期刊
BIOMOLECULES
卷 12, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/biom12101365
关键词
cancer; cisplatin; drug resistance; epigenetics
资金
- ANID-FAPESP [19/13250-1]
- FONDECYT Postdoctoral [3220404]
- ANID [21210202]
Cisplatin is a widely used anti-cancer drug, but tumor cells can develop resistance to its damaging effects through genetic and epigenetic changes, as well as other resistance mechanisms.
Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, alternative splicing, epigenetic-driven expression changes, and even post-translational modifications of proteins. However, the molecular mechanisms by which CDDP resistance develops are not clear but are believed to be multi-factorial. This article highlights a description of cisplatin, which includes action mechanism, resistance, and epigenetic factors involved in cisplatin resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据